Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by LifeGoesOn1973on Sep 23, 2019 1:50pm
167 Views
Post# 30155518

RE:RE:RE:RE:Biggest news Ever

RE:RE:RE:RE:Biggest news Ever
Thank you Bear for pointing this difference (3 and 5 point Mace ) to me,. I didn't see it. I read through your links expecially the analysis you did in OCt 2015, and I am trying to extrapolate the EXAMINE tests (with ACS history with patient) at 18 months for Placebo on diabetic patients and what the event rate would be at 27 month. if we had 10.5 % at 18 months , I think a fair assumption is that the placebo would show 15.75% at 27 month (10.5x27/18). this still gives us 2425 x 0.1575 x 0.5 = 191 Event for the placebo group. total is 275 event so treated group will have 84 event. this is a whooping RRR of 56%. as you said the patient ACS history made the difference and 56% is way over the required 30%. I still think it is very much doable. (would love to read your comments / opinion on this 56% calculation). cheers
Bullboard Posts